Post by
Breakthorough on May 22, 2021 3:56pm
Comparison Stro-002 and DPX
Days ago Sutro Biopharma updated results of Stro-002 in ovarian (last were the 3rd of December). If you look at the DCR ("Disease Control rate", CR+PR+SD) during time, you see: Stro-002: 74% (23 patients) at 12 weeks ; 61% (19 pts) at16 weeks; 16% (5 pts) at 52 weeks. Maveropepimut: 79%; 37% at 26 weeks (6 months); 26'3% at 52 weeks (12 months). Looks like, with time, Maveropepimut (DPX) takes advantage. One can imagine that it will reflect in OS ("Overall Survival") too. Click here the link to www.sutrobio.com: https://finance.yahoo.com/news/sutro-biopharma-announces-additional-data-210000355.html
Comment by
qwerty22 on May 26, 2021 10:49am
Most of the dpx data and KOL feedback screams maintainance therapy or advuvant therapy, but that's a completely different clinical program pathway. This durability is a big part of that.